Refuge Biotechnologies
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1505 Adams Dr Ste D, Menlo Park, Califor...Phone Number
(650) 241-1971Website
www.refugebiotech.comRevenue
$6.8 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
2
1
1
1
1
1
About Refuge Biotechnologies
Refuge Biotechnologies is a synthetic biology company developing intelligent cell therapeutics for cancer immunotherapy. Refuge's proprietary receptor-dCas platform leverages a unique gene engineering approach based on precision CRISPR activation (CRISPRa) and CRISPR interference (CRISPRi). By connecting ligand specific receptors to dCas, Refuge enables cells to sense its surroundings and conditionally activate or repress multiple genes when they encounter specific external antigens. In particular, with receptor-dCas, immune cells can now be engineered to conditionally turn off or on certain immune-inhibitory or immune-stimulatory genes on-demand, to generate more potent CAR-T immune cells when it senses the presence of a tumor cell.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Refuge Biotechnologies your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Check if Refuge Biotechnologies has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Refuge Biotechnologies recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Refuge Biotechnologies is spiking on competitors!
Refuge Biotechnologies, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Refuge Biotechnologies launches new products
Funding: Get notified immidiatlly once Refuge Biotechnologies has new funding data
Congratulate Masked Content for being promoted to Masked Content at Refuge Biotechnologies
Click to see if Refuge Biotechnologies had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Refuge Biotechnologies
Compare insights from companies similar to Refuge Biotechnologies, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Refuge Biotechnologies
$6.8M
11-50
Private
$34.3M
2015
N/A
Company Profile Activity
Activity Insights
Refuge Biotechnologies is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Refuge Biotechnologies is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Refuge Biotechnologies.
Refuge Biotechnologies financials insights
Gather financial insights about Refuge Biotechnologies, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Series A
$8.9M
2018
Series B
$25M
2020
Debt
$350K
Refuge Biotechnologies Tech Stack
A closer look at the technologies used by Refuge Biotechnologies
Refuge Biotechnologies News & Media
Cellectis Appoints Bing Wang, PhD, MBA as Chief Financial Officer - Bollyinside
Prior to joining Cellectis, Dr. Wang was most recently the Chief Executive Officer and Director of Refuge Biotechnologies Inc., a cell therapyMD Anderson and Refuge Biotechnologies Collaborate to Advance Next-Generation Cell Therapies for Treatment of Solid Tumors
HOUSTON & MENLO PARK, Calif.--(BUSINESS WIRE)--Refuge Biotechnologies, Inc. ("Refuge"), a synthetic biology company developing intelligent cell therapeutics for cancer immunotherapy, and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration to advance new cell therapies for potential treatment of solid tumors. The agreement pairs Refuge’s innovative technologies with the experience and industrial capabilities of MD Anderson’s Biologics Development platform,Refuge Biotechnologies Promotes Francesco M. Marincola, MD, to President
Refuge Biotechnologies, Inc. ("Refuge"), a synthetic biology company developing intelligent cell therapeutics for cancer immunotherapy, today announced the promotion of Francesco M. Marincola, M.D., to president. He will retain his role as chief scientific officer.Refuge Biotechnologies Promotes Francesco M. Marincola, M.D., to President
MENLO PARK, Calif.--(BUSINESS WIRE)--Refuge Biotechnologies, Inc. ("Refuge"), a synthetic biology company developing intelligent cell therapeutics for cancer immunotherapy, today announced the promotion of Francesco M. Marincola, M.D., to president. He will retain his role as chief scientific officer. “Since Franco joined Refuge as our chief scientific officer in 2018, he has transformed our immune cell therapy research program into one that can compete with the best in the world. His knowledge
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Refuge Biotechnologies
Sign Up For FreeTo access detailed company insights
Refuge Biotechnologies is a synthetic biology company developing intelligent cell therapeutics for cancer immunotherapy. Refuge's proprietary receptor-dCas platform leverages a unique gene engineering approach based on precision CRISPR activation (CRISPRa) and CRISPR interference (CRISPRi). By connecting ligand specific receptors to dCas, Refuge en... Read More
